ELCC 2019 | Enhancing the efficacy of immunotherapy in lung cancer

Wolf-Hervé Fridman, MD, PhD, of Inserm, Paris, France, addresses the novel therapeutic targets that could help overcome resistance to immunotherapy in lung cancer. Speaking at the European Lung Cancer Congress (ELCC) 2019, held in Geneva, Switzerland, Prof. Fridman discusses the new perspectives on improving immunotherapy efficacy in lung cancer treatment through modulating regulatory T-cells, cytotoxic T-cells, macrophages, and the microbiota.